Company Description
Pliant Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases.
The company’s lead candidate includes bexotegrast, an oral, small-molecule, dual selective inhibitor of αvß6 and αvß1 integrins, which has completed phase 2a trial for primary sclerosing cholangitis.
It also develops PLN-1474, an oral, small-molecule selective inhibitor of αvß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins αvß8 and αvß1 for the treatment of solid tumors; and PLN-101325, a phase 1-ready program for treatment of the muscular dystrophies, including duchenne muscular dystrophy.
Pliant Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
| Country | United States |
| Founded | 2015 |
| IPO Date | Jun 3, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 171 |
| CEO | Bernard Coulie |
Contact Details
Address: 331 Oyster Point Boulevard South San Francisco, California 94080 United States | |
| Phone | 650 481 6770 |
| Website | pliantrx.com |
Stock Details
| Ticker Symbol | PLRX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001746473 |
| CUSIP Number | 729139105 |
| ISIN Number | US7291391057 |
| Employer ID | 47-4272481 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Bernard Coulie M.B.A., M.D., Ph.D. | President, Chief Executive Officer and Director |
| Dr. Keith Lamont Cummings M.B.A., M.D. | Chief Financial Officer |
| Dr. Rik Derynck Ph.D. | Scientific Founder and Member of Scientific Advisory Board |
| Dean Sheppard M.D. | Scientific Founder and Member of Scientific Advisory Board |
| Hal Chapman M.D. | Scientific Founder and Member of Scientific Advisory Board |
| Minnie Kuo | Chief Operating Officer |
| Delphine Imbert Ph.D. | Chief Technical Officer |
| Christopher S. Keenan | Vice President of Investor Relations and Corporate Communications |
| Monica Sandberg Ph.D. | Vice President, Regulatory and Compliance |
| Lily Cheung | Chief Human Resources Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 3, 2026 | 8-K | Current Report |
| Feb 17, 2026 | SCHEDULE 13G/A | Filing |
| Feb 17, 2026 | SCHEDULE 13G/A | Filing |
| Feb 9, 2026 | SCHEDULE 13G | Filing |
| Jan 30, 2026 | SCHEDULE 13G | Filing |
| Jan 22, 2026 | SCHEDULE 13G | Filing |
| Jan 8, 2026 | SCHEDULE 13G/A | Filing |
| Dec 16, 2025 | 8-K | Current Report |
| Dec 8, 2025 | 8-K | Current Report |
| Nov 14, 2025 | SCHEDULE 13G | Filing |